ECSP13012770A - Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina - Google Patents

Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina

Info

Publication number
ECSP13012770A
ECSP13012770A ECSP13012770A ECSP13012770A EC SP13012770 A ECSP13012770 A EC SP13012770A EC SP13012770 A ECSP13012770 A EC SP13012770A EC SP13012770 A ECSP13012770 A EC SP13012770A
Authority
EC
Ecuador
Prior art keywords
phenyl
piperidin
diamine
methyl
isopropoxi
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Lili Feng
Piotr Karpinski
Baoqing Gong
Liladhar Murlidhar Waykole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012770(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP13012770A publication Critical patent/ECSP13012770A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ECSP13012770 2010-12-17 2013-07-16 Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina ECSP13012770A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17

Publications (1)

Publication Number Publication Date
ECSP13012770A true ECSP13012770A (es) 2013-10-31

Family

ID=45464892

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012770 ECSP13012770A (es) 2010-12-17 2013-07-16 Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina

Country Status (36)

Country Link
US (2) US9309229B2 (enExample)
EP (3) EP3453708B8 (enExample)
JP (1) JP5916752B2 (enExample)
KR (4) KR20130130022A (enExample)
CN (7) CN112125884A (enExample)
AR (2) AR084309A1 (enExample)
AU (1) AU2011343775B2 (enExample)
BR (1) BR112013015000A2 (enExample)
CA (1) CA2821102C (enExample)
CL (1) CL2013001723A1 (enExample)
CO (1) CO6801792A2 (enExample)
CY (2) CY1119474T1 (enExample)
DK (2) DK2651918T3 (enExample)
EC (1) ECSP13012770A (enExample)
ES (3) ES2643016T3 (enExample)
GT (1) GT201300153A (enExample)
HR (2) HRP20171477T1 (enExample)
HU (1) HUE041845T2 (enExample)
IL (1) IL226474A (enExample)
LT (2) LT2651918T (enExample)
MA (1) MA34771B1 (enExample)
MX (1) MX338210B (enExample)
MY (2) MY177742A (enExample)
NZ (1) NZ610713A (enExample)
PE (1) PE20140698A1 (enExample)
PH (1) PH12013501254A1 (enExample)
PL (2) PL2651918T3 (enExample)
PT (2) PT2651918T (enExample)
RS (1) RS57771B1 (enExample)
RU (2) RU2746159C2 (enExample)
SG (2) SG10201510082XA (enExample)
SI (2) SI2651918T1 (enExample)
TN (1) TN2013000216A1 (enExample)
TW (2) TWI576343B (enExample)
WO (1) WO2012082972A1 (enExample)
ZA (1) ZA201303599B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2651918T (pt) 2010-12-17 2017-10-17 Novartis Ag Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidin-2,4-diamina
KR102156398B1 (ko) 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Ａｌｋ 키나아제 억제제
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
LT3209647T (lt) 2014-10-21 2020-09-25 Ariad Pharmaceuticals, Inc. Kristalinės 5-chlor-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il) piperidin-1-il]pirimidin-2,4-diamino formos
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (zh) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 色瑞替尼的晶型i及其制备方法
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (en) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Pure amorphous and amorphous solid dispersion of ceritinib
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (zh) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 色瑞替尼的晶型及其制备方法
WO2017158619A1 (en) 2016-03-15 2017-09-21 Natco Pharma Limited A modified process for the preparation of ceritinib and amorphous form of ceritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
CN113135905B (zh) 2020-01-17 2023-11-21 轩竹生物科技股份有限公司 多环类间变性淋巴瘤激酶抑制剂的晶型
KR20230008047A (ko) * 2020-03-30 2023-01-13 장슈 야홍 메디텍 코퍼레이션 리미티드 니트록솔린 전구약물의 결정 형태, 이를 함유하는 약학 조성물, 및 이의 제조 방법 및 이의 용도
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
JP4607879B2 (ja) * 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
RS53588B1 (sr) 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
AU2008296479A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
EP2190826A2 (en) * 2007-08-28 2010-06-02 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
CA2720946C (en) 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors
PT2300013T (pt) * 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
CA2763717A1 (en) * 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
US20130261154A1 (en) 2010-12-17 2013-10-03 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
PT2651918T (pt) * 2010-12-17 2017-10-17 Novartis Ag Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidin-2,4-diamina
HUE038046T2 (hu) 2010-12-17 2018-09-28 Reata Pharmaceuticals Inc Antioxidáns gyulladáscsökkentõ pirazolil és pirimidinil triciklusos enonok
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
US9566882B2 (en) 2014-11-21 2017-02-14 Tk Holdings Inc. Airbag module
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
BR112017011538A2 (pt) 2014-12-04 2018-03-13 Bristol-Myers Squibb Company combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
AR122395A2 (es) 2022-09-07
CN104262324A (zh) 2015-01-07
MX338210B (es) 2016-04-07
EP3453708B8 (en) 2022-03-16
EP3121171B1 (en) 2018-08-15
RU2016136823A3 (enExample) 2020-02-06
MY177742A (en) 2020-09-23
KR102325775B1 (ko) 2021-11-12
RU2013132947A (ru) 2015-01-27
CY1119474T1 (el) 2018-04-04
CO6801792A2 (es) 2013-11-29
GT201300153A (es) 2014-06-09
US20130274279A1 (en) 2013-10-17
CN106831716A (zh) 2017-06-13
SG190856A1 (en) 2013-07-31
RU2599785C2 (ru) 2016-10-20
KR20180032680A (ko) 2018-03-30
RU2599785C3 (ru) 2019-04-24
PH12013501254A1 (en) 2016-07-29
SI3121171T1 (sl) 2018-11-30
TW201307299A (zh) 2013-02-16
CN107056751A (zh) 2017-08-18
NZ610713A (en) 2014-10-31
CL2013001723A1 (es) 2013-12-27
US20160175305A1 (en) 2016-06-23
KR20190022903A (ko) 2019-03-06
ES2905973T3 (es) 2022-04-12
ZA201303599B (en) 2014-02-26
IL226474A (en) 2016-03-31
EP3453708A1 (en) 2019-03-13
DK2651918T3 (en) 2017-10-23
CY1121017T1 (el) 2019-12-11
CA2821102C (en) 2019-06-11
PT2651918T (pt) 2017-10-17
PE20140698A1 (es) 2014-06-11
TWI576344B (zh) 2017-04-01
DK3121171T3 (en) 2018-12-10
PL2651918T3 (pl) 2017-12-29
AU2011343775B2 (en) 2015-12-03
AR084309A1 (es) 2013-05-08
EP2651918B1 (en) 2017-07-12
AU2011343775A1 (en) 2013-07-18
CN106008462A (zh) 2016-10-12
ES2696526T3 (es) 2019-01-16
JP5916752B2 (ja) 2016-05-11
ES2643016T3 (es) 2017-11-21
US9309229B2 (en) 2016-04-12
EP2651918A1 (en) 2013-10-23
TW201629021A (zh) 2016-08-16
EP3121171A1 (en) 2017-01-25
HRP20171477T1 (hr) 2017-11-17
MY164810A (en) 2018-01-30
CN103282359A (zh) 2013-09-04
LT2651918T (lt) 2017-10-10
SI2651918T1 (sl) 2017-10-30
RU2746159C2 (ru) 2021-04-08
MX2013006952A (es) 2013-07-15
JP2013545812A (ja) 2013-12-26
CA2821102A1 (en) 2012-06-21
TWI576343B (zh) 2017-04-01
EP3453708B1 (en) 2021-10-27
WO2012082972A1 (en) 2012-06-21
KR20130130022A (ko) 2013-11-29
TN2013000216A1 (en) 2014-11-10
PL3121171T3 (pl) 2019-01-31
KR20200039021A (ko) 2020-04-14
SG10201510082XA (en) 2016-01-28
MA34771B1 (fr) 2013-12-03
CN112125884A (zh) 2020-12-25
HUE041845T2 (hu) 2019-05-28
HRP20181737T1 (hr) 2018-12-28
CN114989139A (zh) 2022-09-02
RU2016136823A (ru) 2018-12-11
RS57771B1 (sr) 2018-12-31
BR112013015000A2 (pt) 2016-08-09
PT3121171T (pt) 2018-11-27
LT3121171T (lt) 2018-11-12
IL226474A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
MX351507B (es) Composiciones farmaceuticas de co- cristales de tramadol y coxibs.
MX338078B (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
UY33735A (es) Compuestos antivirales
ECSP16093323A (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
MX2020005645A (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido.
BR112014002922A2 (pt) compostos da fórmula i, processo de preparação de compostos da fórmula i, compostos da formula xii, viii e xi, composições agroquímicas, uso e semente
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
MX2015008233A (es) Nuevos derivados de quinolona.
CR20120287A (es) Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2017000101A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
EA201300388A1 (ru) Соединения замещенного бензамида
ECSP14013215A (es) Compuestos novedosos
CR20140553A (es) Compuestos de fenoxietil piperidina
CR20140554A (es) Compuestos de acido dimetil-benzoico
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
CO7141413A2 (es) Proceso para la preparación de derivados de 2-(1-hidroxi-alquil)-cromen-4-ona ópticamente puros y opcionalmente sustituidos y su uso en la preparación de compuestos farmacéuticos
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.